Phio Pharmaceuticals PHIO

Phio Pharmaceuticals Corp. is a clinical stage immuno oncology company that focuses on developing therapeutics using its proprietary INTASYL small interfering RNA gene silencing technology. The INTASYL platform consists of chemically modified small interfering RNA molecules designed to silence genes that tumors use to evade immune detection. These molecules can be administered without the need for specialized formulations or delivery systems such as nanoparticles or electroporation, allowing spontaneous cellular uptake and potent intracellular activity. The company’s lead programs target immune checkpoint proteins and other regulators of tumor immunity with the goal of enhancing the ability of immune cells to kill cancer cells. Phio Pharmaceuticals Corp. is incorporated in Delaware and maintains a remote workforce with a former laboratory space in Worcester Massachusetts and shared office space in King of Prussia Pennsylvania. The company’s pipeline includes PH 762 aimed at programmed death 1 and PH 894 aimed at BRD4 both of which have shown preclinical activity and PH 762 is currently under evaluation in a Phase 1b clinical trial for cutaneous squamous cell carcinoma melanoma and Merkel cell carcinoma.

Phio Pharmaceuticals Corp. has not yet commercialized any therapeutic candidates and therefore does not generate revenue from product sales. The company’s operations are presently focused on research and development activities which have been financed through equity issuances such as the shares delivered to Advirna in connection with the INTASYL technology license agreement and through cash payments including the annual maintenance fee and milestone payments made to Advirna. As a clinical stage entity Phio Pharmaceuticals Corp. has not reported any product sales revenue and its financial statements reflect expenditures primarily associated with preclinical studies clinical trials intellectual property maintenance and general and administrative costs.

The company operates through the following segments.

• Phio Pharmaceuticals Corp. segment: The company’s sole operating segment encompasses all of its research development and commercialization efforts centered on the INTASYL platform. Activities include the design and synthesis of chemically modified small interfering RNA molecules targeting proteins such as programmed death 1 and BRD4 execution of preclinical studies demonstrating anti tumor activity in vitro and in vivo conduct of IND enabling work for candidates like PH 894 and oversight of clinical trials such as the ongoing Phase 1b study of PH 762 in patients with cutaneous squamous cell carcinoma melanoma and Merkel cell carcinoma. The segment also manages intellectual property pursuits including patent prosecution and maintenance engages with contract manufacturing organizations for cGMP production of drug substance and conducts preclinical and clinical safety assessments to support regulatory submissions.

Phio Pharmaceuticals Corp. operates in the highly competitive immuno oncology sector where numerous large pharmaceutical and biotechnology companies possess greater financial resources larger research and development teams and established product portfolios. Despite this the company’s proprietary INTASYL technology offers distinctive advantages that differentiate it from many competitors. The INTASYL platform enables delivery of small interfering RNA to any cell type without requiring specialized formulations nanoparticles or electroporation thereby broadening the range of accessible targets. This capability allows simultaneous silencing of multiple genes and the ability to act on both intracellular and extracellular proteins which is not readily achievable with conventional small molecule or antibody based approaches. Furthermore the company’s data from early clinical trials suggest a favorable safety profile with no dose limiting toxicities observed to date adding to its competitive appeal. Competitors include developers of checkpoint inhibitor antibodies alternative RNAi technologies and cell based immunotherapy companies all of whom strive to modulate tumor immunity but often face limitations related to delivery specificity or manufacturing complexity.

The company’s therapeutic candidates are intended for patients suffering from solid tumors with an initial emphasis on individuals diagnosed with cutaneous squamous cell carcinoma melanoma and Merkel cell carcinoma. These indications represent areas where current treatment options may be limited and where enhancing immune mediated tumor clearance could provide meaningful clinical benefit. While the company has not yet identified specific corporate customers or partnership entities its future products are expected to be administered by healthcare providers such as oncologists and dermatologists in clinical settings such as hospitals outpatient clinics and specialized cancer centers. No specific customer names are disclosed in the filing.